Seberang Jaya Hospital named northern region's specialist heart centre
BUTTERWORTH: Seberang Jaya Hospital has been named the northern region's primary referral centre for cardiology and paediatric cardiothoracic services, a move aimed at easing pressure on Penang General Hospital and improving access to specialist care.
Health Minister Datuk Seri Dr Dzulkefly Ahmad said the upgrade follows the completion of a nine-storey extension at the hospital, significantly expanding its capacity and medical capabilities.
'This will play an important role in decongesting other hospitals in the region,' Dzulkefly said, adding that the enhanced facilities would allow for faster access to complex medical treatment for residents.
He was speaking to reporters after the project's handover ceremony today, which Works Minister Datuk Seri Alexander Nanta Linggi also attended.
With the new block, Seberang Jaya Hospital now houses 729 beds and 11 operating theatres. The facility is expected to begin operations in stages on May 5.
Beyond cardiology and cardiothoracic services, the hospital will host subspecialty departments, including otorhinolaryngology (ENT), paediatric cardiology and rehabilitative medicine, he said.
The RM371 million extension project was first commissioned in 2016 under a design-and-build contract managed by the Public Works Department (JKR).
Dr Dzulkefly also announced that 17 new projects valued at RM9.42 million will be launched under the federal government's Rolling Plan 5 (RP5) within the 12th Malaysia Plan (RMK12).
A further 19 ongoing projects under RMK10, RMK11 and RP4 of RMK12, with a combined value of RM155 million, are also in progress.
Altogether, 36 healthcare projects worth RM165 million are slated for implementation in the state.
On another note, the minister flagged delays in several Health Clinic (KK) projects. Among them is the KK3 Bandar Tasek Mutiara, which has been stalled for nearly a year but is now back on track. Another, KK3 Mak Mandin, approved in 2023, has yet to break ground.
He also called for faster progress on the RM72 million KK2 Bayan Lepas clinic, which received special funding approval from Prime Minister Anwar Ibrahim.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Express
18 hours ago
- Daily Express
Ispire Malaysia says Johor plant operating above board
Published on: Tuesday, June 10, 2025 Published on: Tue, Jun 10, 2025 By: FMT Reporters Text Size: Health minister Dzulkefly Ahmad had said that the Cabinet would decide on the fate of Ispire Malaysia Sdn Bhd's operations in Senai, Johor. (LinkedIn pic) PETALING JAYA: Ispire Malaysia Sdn Bhd today affirmed that its plant in Senai, Johor, which manufactures electronic cigarette devices, is fully compliant with local laws and regulations. In a statement, the firm said it operates under stringent procedures to ensure that all manufacturing activities at its Johor facility are exclusively for export purposes. Advertisement 'To date, Ispire Malaysia exclusively manufactures semi-finished hardware products destined solely for export. 'These products do not contain any nicotine or cannabis – liquid or gel – and thus are not subject to the health ministry's regulations under the Control of Smoking Products for Public Health Act 2024,' it said. It added that the products manufactured in its Johor facility are not marketed, sold, or distributed within Malaysia and not accessible to local consumers. All finished products are exported to regulated international markets such as the US and UK where they are approved for sale by local regulators, the company said. The firm also said that references cited in recent reports were largely drawn from Ispire's official US website and pertained to its business-to-business sales operations in jurisdictions where cannabis and related products are legal. 'These statements do not accurately reflect the operations of Ispire Malaysia, which strictly adheres to all Malaysian laws and regulatory requirements/frameworks,' it said. Health think tank CodeBlue previously reported that Ispire produces nicotine and cannabis-related vaping products, and that its devices are used by clients to fill cartridges with cannabis oils in global markets. The report cited an investor presentation in Las Vegas in April, published on YouTube on May 6, which stated that Ispire produces 'mainly cannabis-related products' in its Malaysian manufacturing facility, which has up to seven production lines. In a statement last week, the health ministry confirmed that the government had issued Ispire an interim nicotine manufacturing licence to produce e-cigarettes with nicotine in its plant in Johor, together with local council approval. However, CodeBlue noted that the ministry's June 2 statement did not mention the plant's production of cannabis vaporisers, which reportedly began in February 2024. Ispire Malaysia today said that any production of nicotine-based products, if initiated, would be strictly for export and subject to formal approval by all relevant government agencies at both federal and state levels. Yesterday, health minister Dzulkefly Ahmad said that the Cabinet would decide on the fate of Ispire's operations in Malaysia. * Follow us on our official WhatsApp channel and Telegram for breaking news alerts and key updates! * Do you have access to the Daily Express e-paper and online exclusive news? Check out subscription plans available. Stay up-to-date by following Daily Express's Telegram channel. Daily Express Malaysia
Free Malaysia Today
20 hours ago
- Free Malaysia Today
Ispire Malaysia says Johor plant operating above board
Health minister Dzulkefly Ahmad had said that the Cabinet would decide on the fate of Ispire Malaysia Sdn Bhd's operations in Senai, Johor. (LinkedIn pic) PETALING JAYA : Ispire Malaysia Sdn Bhd today affirmed that its plant in Senai, Johor, which manufactures electronic cigarette devices, is fully compliant with local laws and regulations. In a statement, the firm said it operates under stringent procedures to ensure that all manufacturing activities at its Johor facility are exclusively for export purposes. 'To date, Ispire Malaysia exclusively manufactures semi-finished hardware products destined solely for export. 'These products do not contain any nicotine or cannabis – liquid or gel – and thus are not subject to the health ministry's regulations under the Control of Smoking Products for Public Health Act 2024,' it said. It added that the products manufactured in its Johor facility are not marketed, sold, or distributed within Malaysia and not accessible to local consumers. All finished products are exported to regulated international markets such as the US and UK where they are approved for sale by local regulators, the company said. The firm also said that references cited in recent reports were largely drawn from Ispire's official US website and pertained to its business-to-business sales operations in jurisdictions where cannabis and related products are legal. 'These statements do not accurately reflect the operations of Ispire Malaysia, which strictly adheres to all Malaysian laws and regulatory requirements/frameworks,' it said. Health think tank CodeBlue previously reported that Ispire produces nicotine and cannabis-related vaping products, and that its devices are used by clients to fill cartridges with cannabis oils in global markets. The report cited an investor presentation in Las Vegas in April, published on YouTube on May 6, which stated that Ispire produces 'mainly cannabis-related products' in its Malaysian manufacturing facility, which has up to seven production lines. In a statement last week, the health ministry confirmed that the government had issued Ispire an interim nicotine manufacturing licence to produce e-cigarettes with nicotine in its plant in Johor, together with local council approval. However, CodeBlue noted that the ministry's June 2 statement did not mention the plant's production of cannabis vaporisers, which reportedly began in February 2024. Ispire Malaysia today said that any production of nicotine-based products, if initiated, would be strictly for export and subject to formal approval by all relevant government agencies at both federal and state levels. Yesterday, health minister Dzulkefly Ahmad said that the Cabinet would decide on the fate of Ispire's operations in Malaysia.
The Star
21 hours ago
- The Star
Value-based healthcare
Medical advances: Dzulkefly (third from right) attending the APHM International Healthcare Conference and Exhibition at the Kuala Lumpur Convention Centre. — YAP CHEE HONG/The Star KUALA LUMPUR: The introduction of basic medical and health insurance/takaful (MHIT) products will mark the first step in the implementation of the diagnosis-related group (DRG) payment model, says Health Minister Datuk Seri Dr Dzulkefly Ahmad. He said MHIT products would steer private healthcare towards a value-based healthcare model with fairer rules for those with pre-existing conditions. 'Introducing DRGs to pay for healthcare services in phases, beginning with this base MHIT product, will be a key driver for value-based healthcare. 'DRGs incentivise efficiency and we expect this will drive innovations in ambulatory and day case surgery, and expand the use of health technologies, which will demonstrate strong cost effectiveness in improving health outcomes while reducing costs,' said Dzulkefly. He added that the Health Ministry is working with the Finance Ministry, Bank Negara and the Employees Provident Fund (EPF) to transform private health insurance and takafuls by developing a base MHIT product. Speaking during the launch of the Association of Private Hospitals Malaysia's (APHM) International Healthcare Conference and Exhibition 2025, he said the Health Ministry has made healthcare financing reform and digitalisation of healthcare services its priority. 'We are also exploring a more diversified health financing ecosystem that combines tax-based allocations, social contributions, employer-based schemes and targeted subsidies, all under a progressive and equitable framework,' he added. Speaking to reporters after the launch, Dzulkefly said the Health Ministry is hoping to introduce the DRG payment model by the end of the year. He said the proposed DRG scheme can start with a simple mechanism in its initial stage. 'Start simple first and after the momentum is developed, go for a complex one,' he added. He also said that Malaysia, especially the APHM and Finance Ministry, have experience in implementing the DRG model. DRG is a payment system that involves paying an amount predetermined by the DRG, instead of paying for each service received. Other countries that have implemented this system include Sweden, Canada and Australia. Dzulkefly was responding to news reports claiming that the government's plans to introduce the DRG system at private hospitals are being put on hold. Commenting on a separate issue, he said the review of consultation fees for private general practitioners (GPs) has been raised to an executive task force chaired by Deputy Prime Minister Datuk Seri Dr Ahmad Zahid Hamidi. Dzulkefly said that after a meeting between the Health Ministry and the National Action Council on Cost of Living (Naccol), it was decided that this issue should be raised to the task force led by Ahmad Zahid. Dzulkefly added that there are no deadlines for finalising the review of consultation fees for private GPs. 'No, but we will tackle this issue at the soonest time possible. 'The Deputy Prime Minister, who chairs the executive task force, will look into the final touches of this,' said Dr Dzulkefly. On May 3, he had said the review of consultation fees for private GPs would be finalised within a month. Yesterday, the Medical Practitioners Coalition Association of Malaysia (MPCAM) had proposed raising private GP fees to a minimum of RM50 and a maximum of RM80. MPCAM had said GP consultation fees have stagnated between RM10 and RM35 for more than three decades since 1992.
